cprice-sewell on PROD1PC66 with NOTICES

Federal Register / Vol. 72, No. 68 / Tuesday, April 10, 2007 / Notices 17917 

Web site at: http:// 

www.videocast.nih.gov/. 

If you have special needs for the 

meeting, please contact (202) 690–7151. 

Dated: April 2, 2007. 

Judith Sparrow, 

Director, American Health Information 

Community, Office of Programs and 

Coordination, Office of the National 

Coordinator for Health Information 

Technology. 

[FR Doc. 07–1762 Filed 4–9–07; 8:45 am] 

BILLING CODE 4150–24–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institute for Occupational 

Safety and Health; Final Effect of 

Designation of a Class of Employees 

for Addition to the Special Exposure 

Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services ((HHS) gives notice 

concerning the final effect of the HHS 

decision to designate a class of 

employees at the General Atomics 

facility, La Jolla, California, as an 

addition to the Special Exposure Cohort 

(SEC) under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000. On February 16, 

2007, as provided for under 42 U.S.C. 

7384q(b), the Secretary of HHS 

designated the following class of 

employees as an addition to the SEC: 

Atomic Weapons Employer (AWE) 

employees who were monitored or should 

have been monitored for exposure to ionizing 

radiation while working at the General 

Atomics facility in La Jolla, California, at the 

following locations: Science Laboratories A, 

B, and C (Building 2); Experimental Building 

(Building 9); Maintenance (Building 10); 

Service Building (Building 11); Buildings 21 

and 22; Hot Cell Facility (Building 23); Waste 

Yard (Buildings 25 and 26); Experimental 

Area (Buildings 27 and 27–1); LINAC 

Complex (Building 30); HTGR–TCF (Building 

31); Fusion Building (Building 33); Fusion 

Doublet III (Building 34); SV–A (Building 

37); SV–B (Building 39); and SV–D (no 

building number) for a number of work days 

aggregating at least 250 work days from 

January 1, 1960, through December 31, 1969, 

or in combination with work days within the 

parameters established for one or more other 

classes of employees in the Special Exposure 

Cohort. 

This designation became effective on 

March 18, 2007, as provided for under 

42 U.S.C. 7384l(14)(C). Hence, 

beginning on March 18, 2007, members 

of this class of employees, defined as 

reported in this notice, became members 

of the Special Exposure Cohort. 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 513– 

533–6800 (this is not a toll-free 

number). Information requests can also 

be submitted by e-mail to 

OCAS@CDC.GOV. 

Dated: April 5, 2007. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 07–1761 Filed 4–9–07; 8:45 am] 

BILLING CODE 4163–19–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institute for Occupational 

Safety and Health; Final Effect of 

Designation of a Class of Employees 

for Addition to the Special Exposure 

Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Department of Health and 

Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) gives notice 

concerning the final effect of the HHS 

decision to designate a class of 

employees at the Monsanto Chemical 

Company, Dayton, Ohio, as an addition 

to the Special Exposure Cohort (SEC) 

under the Energy Employees 

Occupational Illness Compensation 

Program Act of 2000. On February 16, 

2007, as provided for under 42 U.S.C. 

7384q(b), the Secretary of HHS 

designated the following class of 

employees as an addition to the SEC: 

Atomic Weapons Employer (AWE) 

employees who were monitored or should 

have been monitored for exposure to ionizing 

radiation while working at Monsanto 

Chemical Company Units I, III, or IV in 

Dayton, Ohio, for a number of work days 

aggregating at least 250 work days during the 

period from January 1, 1943, through 

December 31, 1949, or in combination with 

work days within the parameters established 

for one or more other classes of employees 

in the Special Exposure Cohort. 

This designation became effective on 

March 18, 2007, as provided for under 

42 U.S.C. 73841(14)(C). Hence, 

beginning on March 18, 2007, members 

of this class of employees, defined as 

reported in this notice, became members 

of the Special Exposure Cohort. 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 513– 

533–6800 (this is not a toll-free 

number). Information requests can also 

be submitted by e-mail to 

OCAS@CDC.GOV. 

Dated: April 5, 2007. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 07–1763 Filed 4–9–07; 8:45 am] 

BILLING CODE 4163–19–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–07–05BW] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–4794 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Survey of Primary Care Physicians’ 

Practices regarding Prostate Cancer 

Screening—New—National Center for 

Chronic Disease and Public Health 

Promotion (NCDDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Prostate cancer is the most common 

cancer in men and is the second leading 

cause of cancer deaths, behind lung 

cancer. The American Cancer Society 

estimated that there would be about 

234,460 new cases of prostate cancer 

and about 27,350 deaths in 2006. 

Although prostate cancer deaths have 

declined over the past several years, it 

ranks fifth among deaths from all 

causes. The digital rectal examination 

(DRE) and prostate specific antigen